|
1
|
Cox D, Brennan M and Moran N: Integrins as
therapeutic targets: lessons and opportunities. Nat Rev Drug
Discov. 9:804–820. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hood JD and Cheresh DA: Role of integrins
in cell invasion and migration. Nat Rev Cancer. 2:91–100. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hynes RO: Integrins: bidirectional,
allosteric signaling machines. Cell. 110:673–687. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Eliceiri BP: Integrin and growth factor
receptor crosstalk. Circ Res. 89:1104–1110. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Desgrosellier JS and Cheresh DA: Integrins
in cancer: biological implications and therapeutic opportunities.
Nat Rev Cancer. 10:9–22. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kreidberg JA: Functions of α3β1 integrin.
Curr Opin Cell Biol. 12:548–553. 2000.
|
|
7
|
Barr LF, Campbell SE, Bochner BS and Dang
CV: Association of the decreased expression of α3β1 integrin with
the altered cell: environmental interactions and enhanced soft agar
cloning ability of c-myc-overexpressing small cell lung cancer
cells. Cancer Res. 58:5537–5545. 1998.
|
|
8
|
Adachi M, Taki T, Huang C, et al: Reduced
integrin α3 expression as a factor of poor prognosis of patients
with adenocarcinoma of the lung. J Clin Oncol. 16:1060–1067.
1998.
|
|
9
|
Lemmon MA and Schlessinger J: Cell
signaling by receptor tyrosine kinases. Cell. 141:1117–1134. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sharma SV, Bell DW, Settleman J and Haber
DA: Epidermal growth factor receptor mutations in lung cancer. Nat
Rev Cancer. 7:169–181. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hynes NE and Lane HA: ERBB receptors and
cancer: the complexity of targeted inhibitors. Nat Rev Cancer.
5:341–354. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Perkins ND: The diverse and complex roles
of NF-κB subunits in cancer. Nat Rev Cancer. 12:121–132. 2012.
|
|
13
|
Kim YK, Lee EK, Kang JK, et al: Activation
of NF-κB by HDAC inhibitor apicidin through Sp1-dependent de novo
protein synthesis: its implication for resistance to apoptosis.
Cell Death Differ. 13:2033–2041. 2006.
|
|
14
|
Cho Y-R, Choi S and Seo D-W: Sepiapterin
regulates cell proliferation and migration: its association with
integrin α3β1 and p53 in human lung cancer cells. Genes Genom.
33:577–582. 2011.
|
|
15
|
Seo D-W, Li H, Qu C-K, et al: Shp-1
mediates the antiproliferative activity of tissue inhibitor of
metalloproteinase-2 in human microvascular endothelial cells. J
Biol Chem. 281:3711–3721. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim S, Cho Y-R, Kim M-D, Kim H, Choi S and
Seo D-W: Inhibitory effects of sepiapterin on vascular endothelial
growth factor-A-induced proliferation and adhesion in human
umbilical vein endothelial cells. Arch Pharm Res. 34:1571–1577.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cho Y-R, Kim SH, Ko HY, Kim M-D, Choi SW
and Seo D-W: Sepiapterin inhibits cell proliferation and migration
of ovarian cancer cells via down-regulation of
p70S6K-dependent VEGFR-2 expression. Oncol Rep.
26:861–867. 2011.PubMed/NCBI
|
|
18
|
Seo D-W, Kim SH, Eom S-H, et al: TIMP-2
disrupts FGF-2-induced downstream signaling pathways. Microvasc
Res. 76:145–151. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hong SY, Cho JY and Seo D-W: Ginsenoside
Rp1 inhibits proliferation and migration of human lung cancer
cells. Biomol Ther. 19:411–418. 2011. View Article : Google Scholar
|
|
20
|
Hodivala-Dilke KM, DiPersio CM, Kreidberg
JA and Hynes RO: Novel roles for α3β1 integrin as a regulator of
cytoskeletal assembly and as a trans-dominant inhibitor of integrin
receptor function in mouse keratinocytes. J Cell Biol.
142:1357–1369. 1998.
|
|
21
|
Gogali A, Charalabopoulos K and
Constantopoulos S: Integrin receptors in primary lung cancer. Exp
Oncol. 26:106–110. 2004.
|
|
22
|
Sherr CJ: The Pezcoller lecture: cancer
cell cycles revisited. Cancer Res. 60:3689–3695. 2000.PubMed/NCBI
|
|
23
|
Mayo MW, Denlinger CE, Broad RM, et al:
Ineffectiveness of histone deacetylase inhibitors to induce
apoptosis involves the transcriptional activation of NF-κB through
the Akt pathway. J Biol Chem. 278:18980–18989. 2003.PubMed/NCBI
|
|
24
|
Stetler-Stevenson WG and Seo D-W: TIMP-2:
an endogenous inhibitor of angiogenesis. Trends Mol Med. 11:97–103.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
DiPersio CM, Shao M, Di Costanzo L,
Kreidberg JA and Hynes RO: Mouse keratinocytes immortalized with
large T antigen acquire α3β1 integrin-dependent secretion of
MMP-9/gelatinase B. J Cell Sci. 113:2909–2921. 2000.PubMed/NCBI
|
|
26
|
Heckman C, Mehew J and Boxer L: NF-κB
activates Bcl-2 expression in t(14;18) lymphoma cells. Oncogene.
21:3898–3908. 2002.
|
|
27
|
Lee HH, Dadgostar H, Cheng Q, Shu J and
Cheng G: NF-κB-mediated up-regulation of Bcl-x and Bfl-1/A1 is
required for CD40 survival signaling in B lymphocytes. Proc Natl
Acad Sci USA. 96:9136–9141. 1999.
|
|
28
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Stipp CS: Laminin-binding integrins and
their tetraspanin partners as potential antimetastatic targets.
Expert Rev Mol Med. 12:e32010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yoshimasu T, Sakurai T, Oura S, et al:
Increased expression of integrin α3β1 in highly brain metastatic
subclone of a human non-small cell lung cancer cell line. Cancer
Sci. 95:142–148. 2004.
|
|
31
|
Seo D-W, Li H, Guedez L, et al: TIMP-2
mediated inhibition of angiogenesis: an MMP-independent mechanism.
Cell. 114:171–180. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Seo D-W, Saxinger WC, Guedez L, Cantelmo
AR, Albini A and Stetler-Stevenson WG: An integrin-binding
N-terminal peptide region of TIMP-2 retains potent angio-inhibitory
and anti-tumorigenic activity in vivo. Peptides. 32:1840–1848.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Morello V, Cabodi S, Sigismund S, et al:
β1 integrin controls EGFR signaling and tumorigenic properties of
lung cancer cells. Oncogene. 30:4087–4096. 2011.
|
|
34
|
Biswas DK and Iglehart JD: Linkage between
EGFR family receptors and nuclear factor kappaB (NF-κB) signaling
in breast cancer. J Cell Physiol. 209:645–652. 2006.PubMed/NCBI
|
|
35
|
Fuster JJ, Sanz-González SM, Moll UM and
Andrés V: Classic and novel roles of p53: prospects for anticancer
therapy. Trends Mol Med. 13:192–199. 2007. View Article : Google Scholar : PubMed/NCBI
|
